To,
Dept of Corporate Services,
BSE Limited,
PJ Towers, Dalal Street,
Fort, Mumbai-400001

Sub: Vanta Bioscience Limited through its subsidiary – Vayam Research Solutions Limited signs CRO Service Agreement of Rs. 29 Crores with Emcure Pharmaceuticals Limited
Ref: BSE Scrip Code: 540729

Pursuant to Regulation 30 of the Listing Regulations, we wish to inform you that Vanta Bioscience Limited's step down subsidiary "Vayam Research Solutions Limited" has entered into a non-exclusive CRO Service Agreement with Emcure Pharmaceuticals Limited, Pune, for providing services of Bio-Analytical and Bio-Equivalence services to the said Company for a period of three years from 2019 to 2022.

The CRO Service Agreement provides for a minimum revenue assurance between Rs. 7.00 crores - Rs.9.00 crores for the financial year 2019-2020 and Rs. 20.00 crores for financial year 2020-2021.

The Trading Window for all designated persons as under Insider Trading Policy of the Company is already closed from Wednesday, April 03, 2019 till 48 hours after declaration of the audited financial results of the Company for the quarter and year ended 31.03.2019 in accordance with our letter to BSE dated April 03, 2019.

This is for your information and for dissemination to the general public at large.

For Vanta Bioscience Limited

S Venkata Rao
CEO & Whole Time Director
DIN: 01448535
Vanta Bioscience Limited through its subsidiary – Vayam Research Solutions Limited signs
CRO Service Agreement of Rs. 29 crores with Emcure Pharmaceuticals Limited

Vanta Bioscience Limited (BSE: 540729) has announced that its step-down subsidiary 'Vayam Research Solutions Limited' has entered into a non-exclusive CRO Service Agreement with Emcure Pharmaceuticals Limited, Pune, for providing services of Bio-Analytical and Bio-Equivalence services to the Company for a period of three years from 2019 to 2022. The development was shared with BSE – the designated Stock Exchange.

The CRO Service Agreement provides for a minimum revenue assurance between Rs. 7.00 crores - Rs.9.00 crores for the financial year 2019-2020 and Rs. 20.00 crores for financial year 2020-2021.

Speaking on the development, Mr. Dophe Raja Mulakala, Managing Director, Vanta Bioscience Limited, said, “This deal broadens our horizon. With a steady and assured revenue, we are further encouraged to shorten the timeframe for dominating the category. We now have state-of-the-art facility and world-class expertise to offer services as per global standards. We are confident that we will deliver impeccable results and add continuously value to their business. It is a matter of pride to be associated with an established company like Emcure Pharmaceuticals.”

The official spokesperson of Emcure Pharmaceuticals Ltd. added, “Service-efficiency, confidentiality and belief in team in-charge of execution are important factors for selecting the service providers for carrying out our bio-analytical and bio-equivalence studies and we believe that Vayam has the capabilities.”

About Vanta Bioscience Limited

Vanta Bioscience Limited, a BSE Listed Company, is a preclinical contract research firm, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition, it also provides risk assessment services for evaluating the safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. Besides, The Company also provides expert services for determination of health-based exposure limits (e.g. permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharma sector. Among the major services of Vanta Bioscience is conducting of variety of in-vitro (cell, tissue & organisms) and in-vivo (animal) toxicology studies for its diverse clients as per regulatory requirements from across the world. The Company has research laboratories in Chennai, India and is managed by industry veterans and experts. Complying with OECD GLP, ISO, AAALAC & USFDA GLP (21 CFR Part 58) guidelines, Vanta has been established as a center of excellence for OECD GLP toxicology services. More information can be availed on: www.vantabio.com